Investigating time lags and attribution in the translation of cancer research
A case study approach
Download eBook for Free
| Format | File Size | Notes |
|---|---|---|
| PDF file | 3 MB | Use Adobe Acrobat Reader version 10 or higher for the best experience. |
In 2012, RAND Europe and the Health Economics Research Group (Brunel University) were commissioned by the Wellcome Trust, Cancer Research UK, the National Institute for Health Research and the Academy of Medical Science to conduct a study of the returns to the public/charitable investment in cancer-related research. This study built on previous work published in the 2008 'What's it worth?' report that estimated the economic returns to medical research in terms of spillover benefits and health gain. The 2008 study was extensively quoted and cited as a clear justification for the economic importance of medical research and appears to have played a role in achieving the protection of the medical science budget in the recent public expenditure cuts.
This cancer study used a similar approach to that used in the previous study, but with some methodological developments. One of the methodological developments was the inclusion of case studies to examine the validity and variability of the estimates on elapsed time between funding and health gains, and the amount of health gains that can be attributed to UK research. This report provides the full text of the five case studies conducted as well as some discussion of observations emerging across the case study set.
Table of Contents
Chapter One
Introduction
Chapter Two
Case study 1: The use of guaiac-based faecal occult blood test in bowel cancer screening
Chapter Three
Case Study 2: Service configuration
Chapter Four
Case study 3: Smoking reduction
Chapter Five
Case study 4: The use of tamoxifen in the treatment of breast cancer
Chapter Six
Case study 5: Total mesorectal excision (TME) in rectal cancer
Chapter Seven
Discussion and observations
Research conducted by
The research described in this report was prepared for the Wellcome Trust, Cancer Research UK, the National Institute for Health Research and the Academy of Medical Science and was conducted by RAND Europe.
This report is part of the RAND Corporation Research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.